Veterinary Healthcare Industry Overview

The veterinary medical equipment market consists of sales of veterinary medical equipment and related services by entities (organizations, sole traders, and partnerships) that produce veterinary medical equipment used in the diagnosis, monitoring, and treatment of medical conditions in animals. This industry includes establishments that produce veterinary surgical equipment such as endoscopic systems, dental equipment, veterinary telemetry services, and others. The main types of veterinary medical equipment are veterinary diagnostic equipment, veterinary anesthesia equipment, veterinary patient monitoring equipment, other veterinary medical equipment that are used for the animals such as small companion animals, large animals, other animals. Veterinary anesthesia equipment refers to the equipment that is used for the animals to provide anesthesia. The products used are instruments/equipment, and disposables. These are used in veterinary hospitals, veterinary clinics, and research institutes. The global veterinary medical equipment market size is expected to grow from $2.02 billion in 2021 to $2.23 billion in 2022 at a compound annual growth rate (CAGR) of 10.7%. The global veterinary medical equipment market size is expected to grow to $3.18 billion in 2026 at a CAGR of 9.2%. The global economy is expected to go through a continued period of steady growth during the forecast period. The USA economy showed steady growth during the historic period, and this is likely to continue during the forecast period. Emerging markets reached4.8% in 2020 versus 3.6%. The continued economic growth is expected to contribute to increased standards of living of the global population and strengthen the presence of the middle class. Increased standards of living and strengthened middle class will further drive the demand for improved nutrition, particularly animal protein, and increase focus on food quality and safety, supporting the growth of the animal medicine market in terms of feed additives. Thus, economic growth is expected to drive this market The outbreak of the Coronavirus disease (COVID-19) has acted as a massive restraint on the veterinary medical equipment market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and spread globally including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of lockdown and the outbreak hurt businesses throughout 2020 and into 2021. However, it is expected that the veterinary medical equipment market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy Advances in diagnostic tools have improved veterinary services. Equipment such as portable x-ray and portable ultrasound scanners have increased the efficiency of veterinary treatment (especially in emergencies due to injury) for all equine/large animals, companions, exotic and mixed animal practices. For example, Wristscan V9, a diagnostic device, is being used for pregnancy tests for animals. Also, the Alivecor app integrated with iPhone is used to perform electrocardiograms in animals for cardiologist review. Major companies in the veterinary medical equipment market include Carestream Health, IDEXX Laboratories Inc., Agfa Healthcare, MinXray Inc., and Diagnostic Imaging Systems. North America was the largest region in the veterinary medical equipment market in 2021. Asia Pacific was the second-largest region in the global veterinary medical equipment market. The regions covered in the global veterinary medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary medical equipment market include Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The global veterinary medical equipment market is segmented - 1) By Type: Veterinary Diagnostic Equipment, Veterinary Anesthesia Equipment, Veterinary Patient Monitoring Equipment, Others 2) By Product: Instruments/Equipment, Disposables 3) By Animal Type: Small Companion Animals, Large Animals, Others 4) By End-User: Veterinary Hospitals, Veterinary Clinics, Research Institutes

The medical feed additives market consists of sales of medical feed additives and related services to prepare complete food for animals. Medical feed additives help improve the nutritional content and quality of feed, results in better productivity, and prevent animals from diseases. The medical feed additives industry includes companies that produce animal feed additives such as vitamins and probiotics, preservatives, antioxidants, digestibility enhancers, gut flora stabilizers, and others. The main types of medical feed additives are antioxidants, antibiotics, probiotics and prebiotics, enzymes, amino acids. The antioxidants refer to the feed additives that are fed to the animals for nutrition. The different mixtures include supplements, concentrates, premix feeds, base mixes. The various classes include typing a type b, type c. These are used by the different livestock such as ruminants, poultry, swine, aquaculture. The global medical feed additives market size is expected to grow from $13 billion in 2021 to $14.48 billion in 2022 at a compound annual growth rate (CAGR) of 11.4%. The global medical feed additive market size is expected to grow to $20.86 billion in 2026 at a CAGR of 9.6%. An increase in the prevalence of diseases among animals is driving the growth of the medicated feed additives market According to the estimates from a report by the Animal and Plant Health Agency, a total of 3289 new TB herd incidents were detected in England. A new herd incident is a case of bovine TB that occurs as a result of a herd or individual animal test performed in an officially TB-free (OTF) herd during the study period. Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals causing illness, coughing, and eventual death. Moreover, according to the reports, the herd incidence rate in England for the 12 months to end September 2020 was 9.4. The additives help prevent animals from diseases alongside increasing the nutrition level of the feed thereby increasing demand for feed additives. The overuse and inappropriate use of antibiotics in medical feed additives impact the health of individuals consuming animal meat or other related products. Moreover, the health of the animal consuming the feed may also be adversely affected by the antibiotics added to the feed as the excess additive reduces the natural immunity of the animal and increases the susceptibility of the livestock to infections. For instance, in July 2020, the Ministry of Agriculture and Rural Affairs in China, under Announcement No. 194 banned the production of commercial feed with medicated feed additives (excluding traditional Chinese medicine) for growth-promoting purposes The negative effects of additives on human health caused due to overuse of feed additives in animals will restrain the growth of the market. Companies in the medical feed additives market are introducing new feed medicated additives formed as a result of a combination of two or more medicated feed additives. More than 70% of manufacturers are now using more than one feed additive in animal feed to increase the efficiency of the product. For instance, Zoetis, a global health company got the approval for its Cyden and Lincomix combination feed additive from the FDA (Food and Drug Administration) and is proposed to be used as a medicated feed additive for poultry. Also, the FDA-approved combination of Zoetis’ feed additives ACTOGAIN 45 (ractopamine hydrochloride) and ENGINE (ractopamine hydrochloride) makes more lean muscle and less fat while optimizing feed efficiency. The medical feed additives market is regulated by government agencies that lay down regulations to be followed by all the manufacturers of veterinary medicines. For instance, the Veterinary Medicines Regulations (VMR) 2013 makes provision for the authorization, manufacturing, and classification of veterinary products including medicated feed additives. The Schedule 5 under EU guidelines covers medicated feeding stuff and specified feed additives which specify guidance to both manufacturers and suppliers of veterinary medicines for incorporating it into animal feed as well as to veterinary surgeons, animal keepers, and other members involved in the use of veterinary medicines and SFAs(Specified Feed Additives)in animal feeding stuff. In February 2019, Archer Daniels Midland Company (ADM), an American global food processing and commodities trading company acquired Neovia for $1.74 billion (€1.544 billion). This acquisition helps ADM to become a global leader in animal nutrition products and services with Neovia adding a wide range of products to the former company’s portfolio including pet care, additives, aquaculture, and livestock feed which would, in turn, boost the growth of the company. Neovia is headquartered in France was established in 1954 and manufactures and distributes various biologically degradable disinfectants along with feed additives for plants and animals. Major players in the medical feed additives market are Zoetis Inc., Cargill, Incorporated, CHS Inc., Purina Animal Nutrition, Archer Daniels Midland Company, Adisseo France Sas, Alltech Inc., Hipro Animal Nutrition, BASF SE, Biostadt India Limited. North America was the largest region in the medical feed additives market in 2021. Asia-Pacific was the second-largest region in the global medical feed market. The regions covered in the global medical feed additives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the medical feed additives market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The global medical feed additives market is segmented - 1) By Type: Antioxidants, Antibiotics, Probiotics and Prebiotics, Enzymes, Amino Acids 2) By Livestock: Ruminants, Poultry, Swine, Aquaculture 3) By Mixture Type: Supplements, Concentrates, Premix Feeds, Base Mixes 4) By Class Type: Type A, Type B, Type C

The veterinary anesthesia equipment market consists of sales of veterinary anesthesia equipment and related services. Veterinary anesthesia equipment is used to deliver anesthetic agents into patients' bodies to prevent pain or discomfort during surgical procedures. The main types of veterinary anesthesia equipment market are standalone anesthesia machines, portable anesthesia machines and are used for small and large animals. The standalone anesthesia machines refer to the equipment that provides anesthesia to the animals. These are used in veterinary hospitals, veterinary clinics, emergency service centers, veterinary homecare settings. The global veterinary anesthesia equipment market size is expected to grow from $0.65 billion in 2021 to $0.72 billion in 2022 at a compound annual growth rate (CAGR) of 11.2%. The global veterinary anesthesia market size is expected to grow to $1.04 billion in 2026 at a CAGR of 9.7%. The rising prevalence of oral diseases in dogs and cats is driving the market for veterinary anesthesia equipment used during oral examinations. Diagnosis and treatment of oral diseases, dental cleaning requires pet animals to be under general anesthesia as it is difficult to handle animals when they are awake and conscious. According to the American Veterinary Dental College, periodontal disease is the most common clinical condition occurring in adult dogs and cats. Thus, the rising prevalence of oral diseases in pet animals is increasing the demand for veterinary anesthesia equipment driving the market growth. The high prices of veterinary anesthetic equipment are acting as a restraint on the market. It is expensive for small veterinary hospitals and clinics to buy and maintain anesthesia equipment, thereby limiting market penetration. The high price of the equipment can be attributed to the advanced technology used in the equipment. Veterinary anesthesia equipment manufacturers are introducing products with advanced features to provide safe and reliable treatment. The new products being introduced offer solutions to problems like power failure, battery failure or exhaustion, and failure of electronic components. Companies such as DRE veterinary and Supera have been investing in introducing anesthetic machines with safety features. Manufacturers of veterinary anesthesia equipment are required to adhere to stringent regulations set by various regulatory bodies. For instance, the US Food and Drug Administration’s (FDA) Center for Veterinary Medicine (CVM) regulates the market for veterinary devices in the USA. The FDA issues guidelines concerning manufacturing, procuring, packaging, branding, selling, and usage of medical devices. Also, the FDA encourages veterinarians and pet owners to report defects in veterinary medical equipment. Major players in the veterinary anesthesia equipment market are JD medical, Midmark Corporation, Smiths Medical, Mindray Medical, Kent Scientific, Everest Veterinary Technology, Dispomed Ltd., Henry Schein Company, Mediquip, and Patterson Scientific. North America was the largest region in the veterinary anesthesia equipment market in 2021. Asia Pacific was the second-largest region in the global veterinary anesthesia equipment market. The regions covered in the global veterinary anesthesia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the veterinary anesthesia equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The global veterinary anesthesia equipment market is segmented - 1) By Type: Standalone Anaesthesia Machines, Portable Anaesthesia Machines 2) By End-User: Veterinary Hospitals, Veterinary Clinics, Emergency Service Centres, Veterinary Homecare Settings 3) By Animal Type: Small, Large

The veterinary patient monitoring equipment market consists of the sale of veterinary patient monitoring equipment which is used to monitor animals' respiration, blood pressure, and other vital signs. Veterinary patient monitoring equipment is used to monitor the animals to detect diseases at early stages to prevent any risks. The veterinary patient monitoring equipment industry includes companies that manufacture monitoring devices to detect diseases that affect animals. The main types of veterinary patient monitoring equipment are cardiac monitoring devices, respiratory monitoring devices, remote patient monitoring devices, multi-parameter monitoring devices, neuromonitoring devices, and other products. The cardiac monitoring devices refer to the devices that deal with animal cardiac diseases. These are used for the animals such as small companion animals, large companion animals, wild animals, zoo animals, aquatic animals, exotic animals. Veterinary patient monitoring equipment is used in veterinary hospitals, veterinary clinics, veterinary research centers. The global veterinary patient monitoring equipment market size is expected to grow from $0.38 billion in 2021 to $0.42 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The global veterinary patient monitoring market size is expected to grow to $0.59 billion in 2026 at a CAGR of 8.7%. An increase in the prevalence rate of diseases among animals serves as one of the major drivers for the veterinary patient monitoring equipment market. An increase in the incidence of diseases in livestock and companion animals will require monitoring equipment to diagnose the diseases among animals. For instance, according to the Banfield Pet Hospital's 2020 Veterinary Emerging Topics (VET) Report, more than 50% of the dogs at 1,000 hospitals in 2019 were overweight or obese. Overweight pets are more likely to suffer from joint disease, respiratory disease, and other preventable conditions. The increase in the prevalence rate of diseases for animals results in increased demand for enhanced veterinary patient monitoring equipment. The veterinary patient monitoring equipment is highly expensive. The price of equipment will be a significant expense for a veterinary clinic or hospital. For instance, the price of average wearable devices ranges from $50 to $100 and will likely have a recurring software as a service (SaaS) fee to store & retrieve an animal’s health data analytics. These expenses hinder the growth of the veterinary patient monitoring equipment market. Veterinarians and pet or cattle owners are shifting to wearable technology to keep track of animal behavior. Wearable technology is smart electronic devices that are worn on the body or integrated with clothing or accessories and monitor body temperature, behavior, and movement. These wearable monitoring devices provide timely insights regarding the overall health of the animal and help the veterinarian to provide an appropriate diagnosis to the animal. For instance, Vetrax, a wearable sensor worn on a dog’s collar, enables clinicians and pet owners to monitor aspects of an animal’s behavior when they are unsupervised. According to a report by Veterinary Practice News, 83% of pet owners are satisfied with the use of wearable technology and 68% are finding it an effective way of monitoring the weight and diabetes of their pets. The veterinary patient monitoring equipment market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. EMA should certify the medical devices before they are marketed. EMA verifies the safety and quality of the devices before they can be certified and approved for use throughout the European Union. The EMA requires all the devices to comply with the regulations stated under Directive 2001/82/EC and Regulation (EC) No 726/2004. In April 2019, American pharmaceutical company Merck & Co. headquartered in New Jersey acquired Antelliq for $2.4 billion. Antelliq will now work in Merck's animal health division. This acquisition marks the beginning of the trend for pharmaceutical companies to give equal importance to their veterinary devices as well as their human healthcare equipment. Antelliq, a company in the field of animal identification and monitoring will not only re-establish and widely improve Merck's reach in the veterinary monitoring devices market but will also enhance the quality of the devices. Antelliq is an American company established in 2013 and is headquartered in Dallas, Texas. Major players in the veterinary patient monitoring market are Smiths Group plc, Hallowell Engineering & Manufacturing Corporation, DRE Veterinary, Digicare Biomedical Technology Inc., Midmark Corporation, Medtronic plc., Jorgensen Laboratories, Vetland Medical Sales and Services LLC, Jorgen Kruuse A/S, Mila International Inc., and Mindray Medical International Limited. North America was the largest region in the veterinary patient monitoring market in 2021. Asia Pacific was the second-largest region in the global veterinary patient monitoring market. The regions covered in the global veterinary patient monitoring equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the veterinary patient monitoring market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The global veterinary patient monitoring equipment market is segmented - 1) By Product: Cardiac Monitoring Devices, Respiratory Monitoring Devices, Remote Patient Monitoring Devices, Multi-Parameter Monitoring Devices, Neuromonitoring Devices, Others 2) By End-User: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Centers 3) By Animal: Small Companion Animals, Large Companion Animals, Wild Animals, Zoo Animals, Aquatic Animals, Exotic Animals

The veterinary diagnostic equipment market consists of sales of veterinary diagnostic equipment and related services. Veterinary diagnostic equipment assists veterinary practitioners in determining and identifying various disorders in animals. The veterinary diagnostic equipment industry includes companies that manufacture diagnostic equipment such as clinical thermometers, diagnostic lights, X-ray equipment, and certain diagnostic test kits. The main types of veterinary diagnostic equipment are hematology, immunodiagnostics, clinical chemistry, molecular testing. Hematology refers to the study of the prognosis, cause, and treatment of diseases related to blood. These are used for livestock cattle, domestic pets. The veterinary diagnostic equipment is used in hospitals and clinics, reference laboratories, universities/research centers, point-of-care/in-house testing. The global veterinary diagnostic equipment market size is expected to grow from $0.85 billion in 2021 to $0.94 billion in 2022 at a compound annual growth rate (CAGR) of 10.6%. The global veterinary diagnostics market size is expected to grow to $1.33 billion in 2026 at a CAGR of 9.1%. An increase in the prevalence rate of diseases among animals serves as one of the major drivers of the veterinary diagnostic equipment market. Due to the increase in the incidence of diseases in livestock and pets, the demand for enhanced diagnostic equipment increases. For instance, according to the Banfield Pet Hospital's 2020 Veterinary Emerging Topics (VET) Report, more than 50% of the dogs at 1,000 hospitals in 2019 were overweight or obese. Overweight pets are more likely to suffer from joint disease, respiratory disease, and other preventable conditions. The increase in the prevalence rate of diseases in animals, increases demand for diagnostic equipment, driving the veterinary diagnostic equipment market. The veterinary diagnostic equipment is highly expensive. The price of equipment will be a significant expense for a veterinary clinic or hospital. To run a test center with blood testing machines, physiological monitors such as ECGs, anesthetic monitors, etc, diagnostic imaging techniques such as x-rays, ultrasound, and MRI scanners, is highly capital intensive. Some kind of veterinary diagnostic equipment may be available on a budget, but with less precise diagnoses and thus less efficient treatments with less beneficial results. The high price of equipment hinders the growth of the veterinary diagnostic equipment market. Veterinary diagnostic equipment manufacturers are introducing advanced technologies such as advanced blood microsampling techniques to enable enhanced precision, patient-centered specimen collection, and diagnosis of diseases in animals. Blood microsampling is a technique that allows the participants to draw blood samples from their livestock and companion animals with ease. The samples are then forwarded to labs for further diagnosis. This technique is an extension to dry blood sampling, which is a method of collecting blood. For instance, Neoteryx launched the '3Rs-compliant Mitra' microsampling device that works on the principle of Micro sampling. The device uses Neoteryx's trademark Volumetric Absorptive Micro Sampling (VAMS) technology to facilitate more convenient and accurate remote sampling. Other companies investing in the trend of microsampling include Diatron with its Diatron Aquila hematology analyzer. The US Food and Drug Administration (FDA) defines regulations for veterinary diagnosis equipment and can take appropriate action if veterinary equipment is found misbranded or adulterated. The conditions for misbranding diagnostic equipment are listed under title 21 and set by the Food and Drugs Administration. For instance, as per the regulations under title 21, U.S code 352(f)(1), any veterinary medical equipment is considered misbranded if the labeling on the equipment is indefinite or unclear. Whereas, 21 U.S.C. 352(j) states that veterinary medical equipment is considered misbranded if it is dangerous to the animal even when it is used in the manner recommended, or suggested as per the label. In September 2021, Mindray, a company operating in veterinary imaging equipment based in China acquired HyTest Invest Oy and its subsidiaries for an undisclosed amount. With this acquisition, HyTest company enables Mindray to have top-notch raw material R&D and innovation capabilities and also help in investing in R&D as well as strengthen and improve its competitive edge. Hytest is a company operating in veterinary diagnostic equipment based in Finland. Major players in the veterinary diagnostic equipment market are IDEXX Laboratories, ABAXIS, HESKA Corporation, Zoetis, Virbac, Mindray Medical International Ltd., Neogen Corporation, QIAGEN N.V., Agfa Healthcare, and Toshiba. North America was the largest region in the veterinary diagnostic equipment market in 2021. Asia Pacific was the second-largest region in the global veterinary diagnostic equipment market. The regions covered in the global veterinary diagnostic equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary diagnostic equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, and USA. The global veterinary diagnostic equipment market is segmented - 1) By Product: Hematology, Immunodiagnostics, Clinical Chemistry, Molecular Testing 2) By End-User: Hospitals and Clinics, Reference Laboratories, Universities/Research Centers, Point-Of-Care/In-House Testing 3) By Animal: Livestock Cattle, Domestic Pets

The veterinary vaccines market consists of sales of vaccines and related services which are used for the treatment and prevention of diseases in animals. These veterinary vaccines reduce animal suffering and the transmission of microorganisms in the animal population. Veterinary vaccines are used to enhance the immunity power of animals by improving animal health, which also prevents the transmission of diseases from animals to humans. The various types of veterinary vaccines are live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccine types. Inactivated vaccines differ from live but attenuated vaccines as they are made up of dead, or inactivated, viruses and bacteria. The disease types are anaplasmosis, canine parvovirus, foot and mouth disease, Newcastle disease, distemper disease, influenza, porcine reproductive and respiratory syndrome and the application areas include livestock vaccines, and companion animal vaccines. The global veterinary vaccines market size is expected to grow from $6.82 billion in 2021 to $7.38 billion in 2022 at a compound annual growth rate (CAGR) of 8.2%. The global veterinary vaccine market size is expected to grow to $9.47 billion in 2026 at a CAGR of 6.4%. The increase in the number of animals suffering from a range of diseases is increasing the demand for vaccines to prevent and treat such diseases, thus driving the veterinary vaccines market According to the estimates from a report by the Animal and Plant Health Agency, a total of 3289 number of new TB herd incidents were detected in England Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals causing a general state of illness, coughing and eventually lead to death. However, the disease can be treated with specific antibiotics that kill the TB bacteria. This rising prevalence of diseases in animals is expected to drive the veterinary vaccines market during the forecast period. High storage costs are acting as a major restraint for the growth of the veterinary vaccine market. Improper storage conditions and delays in shipping can cause vaccines to lose their desired immune properties. For example, during transportation, vaccines can undergo biodegradation, if they are not transported within the required temperature limits. Thus, special care is required for the transportation of the vaccines to maintain the efficiency of the vaccines, which increases the storage and transportation cost for the vaccines. According to a report published by the National Institute of Standards and Technology (NIST), approximately 35% of vaccines lost their potencies during the shipment, as they were stored at abnormal temperatures. Thus, high storage costs for vaccines are expected to result in additional costs for manufacturing companies and limit the growth of the market. Companies in the veterinary vaccines market are increasingly looking for strategic partnerships and collaborations to enter into new geographies and to share the Research & Development projects. For example, in 2020, the Pirbright Institute, a UK-based animal disease research institute, partnered with ECO Animal Health, a UK-based Pharmaceutical company, and the Vaccine Group (TVG) to develop porcine respiratory and reproductive syndrome virus (PRRSV) vaccines. The vaccine group is a biotechnology company that develops animal vaccines and is based in Plymouth, UK. Similarly, MSD Animal Health, a division of Merck & Co with headquarters in the US, made a strategic partnership with Vinovo. This partnership will help MSD Animal Health to combine its unique broad vaccine product line and Vinovo’s vaccine delivery system to the vaccination process, thus improving bird welfare, and reducing vaccine reactions. Also, Wageningen bio veterinary research made a strategic alliance with Ceva with headquarters in Switzerland, to improve their Research on the global threat of emerging and reemerging diseases for animals. The veterinary vaccines market is regulated by authorities such as European Medical Agency and the US Center for Veterinary Biologics. For instance, veterinary vaccine companies in Europe are required to adhere to European technical requirements mentioned in Annex 1, Title II, to Directive 2001/82/EC, as amended by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). According to these regulations, veterinary vaccines are required to undergo safety tests before getting approval, where vaccines are classified into activated vaccines and inactivated Vaccines. Inactivated vaccines, each batch of vaccines should have a dose that is double the standard dose. In inactivated vaccines, each batch of vaccines should be ten times the standard dose for the active vaccines. Activated vaccines are usually tested by in vitro titration, while serological tests are commonly used for inactivated vaccines. Major players in the veterinary vaccines market are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, Bayer AG (Bayer Animal Health), Ceva Santé Animale, Virbac, Biovac, Zoetis Animal Healthcare, and Hester Biosciences Ltd. North America was the largest region in the veterinary vaccines market in 2021. Asia-Pacific was the second-largest region in the global animal vaccines market. The regions covered in the global veterinary vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary vaccines market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global veterinary vaccines market is segmented - 1) By Application: Livestock Vaccines, Companion Animal Vaccines 2) By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others 3) By Disease Type: Anaplasmosis, Canine Parvovirus, Foot and Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive and Respiratory Syndrome (PRRS)

The veterinary parasiticides market consists of sales of veterinary parasiticides and related services which are used in the treatment of parasitic diseases in livestock, pets, and other animals. The veterinary parasiticides industry includes establishments that produce a cure to parasitic diseases that can be caused by helminths, amoeba, ectoparasites, parasitic fungi, and protozoa. Veterinary parasiticides are chemical substances that destroy or inhibit micro-organisms or parasites and improve the animals’ health. The main types of veterinary parasiticides are endoparasiticides, ectoparasiticides, and endectocides. Endectocides are medications that are administered directly to hosts to kill endoparasites and ectoparasites, primarily blood-feeding arthropods. The product types include oral liquids, tablets, injectables, sprays, and other products applied on farm animals, and companion animals that are used by R&D facilities, farms, and veterinary clinics. The global veterinary parasiticides market size is expected to grow from $2.48 billion in 2021 to $2.72 billion in 2022 at a compound annual growth rate (CAGR) of 9.7%. The global veterinary parasiticide market size is expected to grow to $3.69 billion in 2026 at a CAGR of 7.9%. The animals are increasingly being affected by zoonotic pathogens which are the leading cause of foodborne diseases worldwide. Zoonotic diseases are infectious diseases caused by bacteria, viruses, and parasites, especially Salmonella and Campylobacter, which can be transmitted directly or indirectly between animals and humans. These diseases get passed through the food chain to humans which is a potential threat and creates a dire need to prevent such diseases among animals. According to the FDA in 2020, about 128,000 hospitalizations and 3,000 deaths were reported in America due to foodborne illness. The necessity to curb these infections in animals drives the market for veterinary parasiticides. Lack of awareness about animal diseases due to limited information on microbes and their impact on wildlife and livestock disease restrains the veterinary parasiticides industry. Lack of awareness about the occurrence of zoonotic diseases and their impact on public health is a major hurdle for the animal parasiticides market. This lack of awareness does not allow people to adopt the parasiticides for livestock/wildlife which not only control different parasitic diseases but also improve animal health. For instance, Proceedings of the National Academy of Sciences (PNAS) reported that only ten diseases account for around 50% of all published knowledge on diseases at the wildlife-livestock interface and the analysis was based on almost 16,000 publications from the last century. The lack of knowledge and awareness will restrain the growth of the market. Chewable tablets are being used to prevent animals from being affected by ticks, worms, fleas, and others. Treatments with these tablets are easier to administer. The chewable tablets are available in either a beef-flavored tablet or soft chew. For instance, the IVERHART MAX chewable tablets protect dogs from the 4 most common worms: heartworms (infection caused by the bite of an infected mosquito), roundworms, hookworms (affects the intestines), and tapeworms (caused by ingesting an infected flea). Such advances in technology are significantly driving the veterinary parasiticides industry. The veterinary parasiticides market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. For instance, under the directive, 2008/97/EC of the European Parliament certain products/drugs which contain substances having a hormonal or thyrostatic action and beta-agonists are banned. Meat or products from food-producing animals which have an oestrogenic, androgenic, or gestagenic action of beta-agonists are prohibited for human consumption unless those animals have been treated with veterinary medicines complying with the requirements of Article 6 of Council Directive 96/22/EC. Major players in the veterinary parasiticides market are Bayer AG, Zoetis, Boehringer Ingelheim, Merck, Eli Lilly and Company, Virbac, Ceva Animal Health, Inc., Merial, Perrigo Company, and Vetoquinol, and Intas Pharmaceuticals Ltd. North America was the largest region in the veterinary parasiticides market in 2021. Asia-Pacific was the second-largest region in the global veterinary parasiticides market. The regions covered in the global veterinary parasiticide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary parasiticides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global veterinary parasiticides market is segmented - 1) By Type: Endoparasiticides, Ectoparasiticides, Endectocides 2) By End-User: R&D Facilities, Farms, Veterinary Clinics 3) By Product: Oral Liquids, Tablets, Injectables, Sprays, Others 4) By Application: Farm Animals, Companion Animals

The veterinary antibiotics market consists of sales of veterinary antibiotics and related services. Veterinary antibiotics are used to fight against infections and diseases in animals caused due to bacteria. The veterinary antibiotics industry includes companies involved in the production of antibiotics used for therapeutic and prophylaxis treatment of animals. The main product types of veterinary antibiotics include anti-parasitic, anti-bacterial, non-steroidal anti-inflammatory drugs, and other products. Non-steroidal anti-inflammatory drugs (NSAIDs) act as a bridge between the production and activity of prostaglandins (enzymes) implicated in inflammation. Approved veterinary NSAIDs are used in companion animal care to reduce the pain and swelling linked with osteoarthritis in dogs and horses. The administration of veterinary antibiotics includes premixes, injections, oral powders, oral solutions, and other administration used on farm animals and companion animals. The global veterinary antibiotics market size is expected to grow from $0.28 billion in 2021 to $0.31 billion in 2022 at a compound annual growth rate (CAGR) of 8.1%. The global veterinary antibiotic market size is expected to grow to $0.39 billion in 2026 at a CAGR of 6.3%. An increase in the number of zoonotic diseases is driving the veterinary antibiotics market. Zoonotic diseases are infectious diseases caused by microscopic organisms, infections, and parasites that spread between animals and humans. Two of the most common zoonotic pathogens salmonella and campylobacter are present in the intestines of these animals. Zoonotic diseases are also a potential threat to humans as they get transferred through the food chain. A study conducted by the FoodNet (Centers for Disease Control and Prevention, USA) found that 24,484 foodborne illnesses, 5,677 hospitalizations, and 122 deaths are caused due to zoonotic diseases. In addition, the highest incidences per 100,000 population in the USA are caused due to infectious diseases such as campylobacter, salmonella, and shigella. Therefore, there is a need to diagnose these diseases in animals at an early stage, which is a major driver of the veterinary antibiotics market. The rising threat of antibiotic resistance is a major restraint for the veterinary antibiotics market. Antibiotic resistance in animals is the ability of a microbe to withstand the impact of an antibiotic that once could successfully treat the infection from the same type of microbe. This can be a result of using antibiotics more than the prescribed limit. In this regard, the European Union (EU) has approved various restrictions on veterinary antibiotics including a ban on antibiotics for animals and prohibiting the usage of antimicrobials in food, which is restricting the growth of the veterinary antibiotics market. Increasing collaboration between companies is an emerging trend in the veterinary antibiotics market. Collaboration offer companies to combine technologies and a wide range, more diversified portfolio of products to work with, and it also improves the quality of the antibiotics and the speed at which they are producing. Therefore, companies in the veterinary antibiotics market are focusing on collaborations. For example, in April 2019, Bayer AG entered into a strategic collaboration with Adiva GmbH to develop therapeutic antibodies for veterinary medicine. The veterinary antibiotics prescription drugs market is regulated by Section 503(f) of the Food, Drug, and Cosmetic Act of FDA. According to this law, the veterinary antibiotics drug labels are mandated to include a caution statement that states that these drugs can only be used with the permission of a licensed veterinarian. The sale and use of antibiotics prescription drugs without a prescription are usually reported to the FDA and strict action is taken based on it. Hence, regulations such as these would regulate veterinary antibiotics manufacturers and sellers. Major players in the veterinary antibiotics market are Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale, Eli Lilly Company, Elanco, Merck & Co, Sanofi, Virbac, Zoetis, and Crystal Pharma. North America was the largest region in the veterinary antibiotics market in 2021. Asia-Pacific was the second-largest region in the global veterinary antibiotics market.The regions covered in the global veterinary antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary antibiotics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global veterinary antibiotics market is segmented - 1) By Product: Anti-Parasitic, Anti-Bacterial, Non-Steroidal Anti-Inflammatory Drug, Others 2) By End-User: Farm Animals, Companion Animals 3) By Administration: Premixes, Injections, Oral Powders, Oral Solutions, Others